Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Elsevier Business Intelligence and Windhover Conferences have announced a major addition to the lineup for their upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In Roche and Genentech: Understanding Their Collaborative Business Development Model, the two executives who designed and implemented the radical new collaborative business model will share exactly how they make this relationship work and the outlook for the business model in the future.

Mary Graves, Executive Director, Roche Pharma Partnering, and Suzy Jones, Senior Director of Business Development, Genentech Partnering, will outline Roche's strategy for retaining Genentech's business development team despite taking the company private. The executives will discuss a variety of strategies, including:

-- Early stage, late stage and TAs, and who does what deal -- Who to talk to about partnering based on asset stage and therapeutic area -- Strategic priorities in the merged company -- Commercializing licensed products after the merger

Therapeutic Area Partnerships will also feature its popular Top 10 Projects to Watch, including a Top 10 in each of four therapeutic areas: cardiovascular/metabolic, oncology, neuroscience and inflammatory/autoimmune. According to Roger Longman, Managing Director, Pharma, of Elsevier Business Intelligence, many companies previously featured on the Top 10 list have gone on to negotiate major deals.

The complete list of all projects to date (in random order) is available at www.windhover.com/taprojects. Each project has been hand-selected by Windhover's elite selection panel to ensure a high-quality slate of presenters.

Companies will present the product's target and first indication(s); other compounds addressing the same target; the relative advantage of the compound; the clinical results to date and general clinical plan for the future; IP on the compound or target; and any partnerships the company currently holds on the compound. Registered attendees have access to pre-conference access to a database that includes detailed technical, non-confidential information on projects available for partnering (pre-clinical and clinical stage).

Industry analysts will open each Top 10 session with therapy area-specific discussions on Matchmaking in Drug Partnering: Identifying the Right Drugs and the Right Partners